Cost-effectiveness analysis evaluating Factor VIII as primary prophylaxis treatment for patients with severe haemophilia A in The Netherlands

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Last time updated on 15/10/2017